Graves' Ophthalmopathy Clinical Trial
The exact mechanism of the pathogenesis of Graves’ ophthalmopathy is still unknown.
Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two
prominent changes. In the past year, we had investigated the morphological features of the
Müller muscle in patients with thyroid lid retraction using the special stain and
immunohistochemistry. In our findings, the smooth muscle cells, in the diseased group, were
replaced by variable adipose and fibrosis tissues.
In recent years, TSHR, has been verified to express in orbital connective tissue and
extra-ocular muscle. From functional studies and an increase in adipogenesis in cultured
fibroblasts with expression of TSHR protein, the role not only the target but effector cells
in orbital fibroblasts were validated. Quantitative RT-PCR may help to differentiate whether
a less extent of expression at the end stage or low protein amount to be detected.
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of
Thy-1 protein or not, had been reported from several studies, the investigators believed
heterogeneity in orbital fibroblast may determine the clinical presentation of
Graves’ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the
fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological
features of adipogenesis and fibrosis.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with
systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of
several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have
a close relationship with adipogenesis. We hypothesize that some immunological processes
involve the ocular adnexal and orbital tissues, which result in various ophthalmological
manifestations.
The purpose of this study is to investigate the different stage of the ocular adnexal and
orbital tissues to identify the pathogenesis of Graves' ophthalmopathy by frozen sections
with Immunohistochemistry, mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and
different cytokines using quantitative RT-PCR and flow cytometry at the acute and stable
stage in GO.
The exact mechanism of the pathogenesis of Graves’ ophthalmopathy (GO) is still unknown.
Histopathologically, extraocular muscle inflammation due to lymphoid infiltration, edema and
interstitial fibrosis, and increased glycosaminoglycan deposition and orbital fat
inflammation are two prominent changes. There are various manifestations including ocular
adnexal tissues inflammation, proptosis, lid retraction, extraocular movement limitation and
compressive optic neuropathy. In the past year, we had investigated the morphological
features of the Müller muscle in patients with thyroid lid retraction using the special
stain and immunohistochemistry in formalin-fixed paraffin-embbeded (FFPE) sections. In our
findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose
and fibrosis tissues. Two distinct features in the disease group seem to be notable for
further investigation.
In recent years, TSHR, a putative autoantigen, has been verified to express in orbital
connective tissue and extra-ocular muscle. In addition, they were further demonstrated to
express on the surface of cultured orbital fibroblasts and orbital adipose tissue, in
patients with GO in several laboratories. From functional studies and an increase in
adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the
target but effector cells in orbital fibroblasts were validated7. We used
immunohistochemistry to verify the existence of TSHR on the fibroblasts within the Müller
muscle, and the positive staining is manifested in only18 % of patients. It may due to a
less extent of expression at the end stage. We are very curious to know if there any
difference on the expression of TSHR between orbital specimens from patients with acute and
those with stable stage. Quantitative RT-PCR may help to differentiate whether a less extent
of expression at the end stage or low protein amount to be detected.
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of
Thy-1 protein or not, had been reported from several studies, the investigators believed
heterogeneity in orbital fibroblast may determine the clinical presentation of Graves’
ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the
fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological
features of adipogenesis and fibrosis. In addition, systemic or local pro-inflammatory
cytokines may contribute to turn on and turn off the expression of different roles of the
fibroblasts.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with
systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of
several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have
a close relationship with adipogenesis. In our previous study, the smooth muscle cells, in
the diseased Mullers’ muscle, were replaced by variable adipose and fibrosis tissues. The
increased adipose and fibrosis tissue ex vivo of the Müller’ muscle may result from
over-action of some biochemical markers in the fibroblasts infiltrating around muscle cells.
We hypothesize that some immunological processes involve the ocular adnexal and orbital
tissues, which result in various ophthalmological manifestations.
The purpose of this study is to investigate the different stage ( acute or stable stage) of
the ocular adnexal and orbital tissues ( including orbital fat, extraocular muscles,
orbicularis muscles and eyelid fat) to identify and validate the pathogenesis of Graves
ophthalmopathy by frozen sections of the ocular adnexal and orbital tissues with
Immunohistochemistry (IHA) (Thy-1 and PPARγ), mRNA expression of TSH receptor, PPAR-γ,
IGF-1R, and IGF-1 and different cytokines (IL-1β, IL-4, IL-6, IL-8) using quantitative
RT-PCR and flow cytometry at the acute and stable stage in GO.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02059655 -
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
|
Phase 4 | |
| Completed |
NCT02721992 -
Graves' Orbitopathy and Hypercholesterolemia
|
N/A | |
| Recruiting |
NCT02290704 -
Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People
|
N/A | |
| Recruiting |
NCT01969019 -
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
|
Phase 4 | |
| Recruiting |
NCT01056419 -
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
|
Phase 4 | |
| Completed |
NCT00697528 -
Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
|
N/A | |
| Completed |
NCT00430547 -
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
|
N/A | |
| Completed |
NCT03922321 -
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
|
Phase 2 |